|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006141,
umls-concept:C0007124,
umls-concept:C0017262,
umls-concept:C0034833,
umls-concept:C0185117,
umls-concept:C0242957,
umls-concept:C0330390,
umls-concept:C0665341,
umls-concept:C1366563,
umls-concept:C1418986,
umls-concept:C1515021,
umls-concept:C2911684
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-9-17
|
|
pubmed:abstractText |
Antiestrogen therapy of ductal carcinoma in situ (DCIS) has become a more common option in reducing risk of developing invasive cancer. Previously, estrogen receptor alpha (ER-alpha) was evaluated as the only predictive factor. Immunohistochemical staining was performed for ER-alpha, estrogen receptor ER-beta, progesterone receptor (PR), pS2 and her-2/neu in 59 cases of ductal carcinoma in situ (DCIS). We observed a positive correlation between the expression of ER-alpha (p=0.003), PR (p<0.001) and histopathological grading. Of the DCIS, 61.5% of ER-beta positive (p=0.046) and 35.5% of PR positive samples showed a coexpression with pS2, whereas 72.1% of pS2 negative DCIS were also negative for ER-beta and 92.9% of PR negative DCIS were negative for pS2 (p=0.012). In contrast, 50.0% of her-2/neu negative DCIS expressed ER-beta receptor (p=0.052). We propose that there are subpopulations of DCIS which can be described by distinct endocrine-associated expression patterns.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor beta,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PSEN2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Presenilin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1021-335X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
695-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15375487-Adolescent,
pubmed-meshheading:15375487-Adult,
pubmed-meshheading:15375487-Aged,
pubmed-meshheading:15375487-Aged, 80 and over,
pubmed-meshheading:15375487-Breast Neoplasms,
pubmed-meshheading:15375487-Carcinoma, Intraductal, Noninfiltrating,
pubmed-meshheading:15375487-Estrogen Receptor alpha,
pubmed-meshheading:15375487-Estrogen Receptor beta,
pubmed-meshheading:15375487-Female,
pubmed-meshheading:15375487-Humans,
pubmed-meshheading:15375487-Immunoenzyme Techniques,
pubmed-meshheading:15375487-Membrane Proteins,
pubmed-meshheading:15375487-Middle Aged,
pubmed-meshheading:15375487-Presenilin-2,
pubmed-meshheading:15375487-Prognosis,
pubmed-meshheading:15375487-Receptor, erbB-2,
pubmed-meshheading:15375487-Receptors, Progesterone,
pubmed-meshheading:15375487-Tumor Markers, Biological
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, University of Hospital of Muenster, Germany. achim.rody@em.uni-frankfurt.de
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
